1 min read
On-Demand Webinar: Large-Scale LVV Production: Industry-Leading Process Development to High Quality GMP Vector
Nick McDonald February 25, 2021 at 12:00 PM
The on-demand webinar and Q&A “Large-Scale LVV Production: From Industry-Leading Process Development to High Quality GMP Vector,” with our own Giuliana Vallanti, Director of Development and Global R&D, Cell and Gene Therapy, and the panel of co-hosts is now available to watch for free.
About the Webinar
In recent years, Lentiviral vector (LVV) has become a vector of choice used in gene-modified cell therapy. A standard GMP 48L Cell Factory (CF)-based process is not enough to meet the manufacturing demand – especially for commercial applications. In response to this demand, AGC Biologics has developed a reproducible, high quality and quantity process for the industrial scale production of LVV. This platform consists of vector production in the iCELLis® Bioreactor, downstream purification and concentration by chromatography and TFF steps, and sterile filtration & filling.
Giuliana shared the latest data that demonstrates the key advantages of our proven approach to scale the LVV production process (48L CF) in a bioreactor (200L) without changing critical quality attributes (CQA).
Register to watch for free today.
This webinar was presented in partnership with InsightsBio.
![Video: Ensuring successful process development for GMP manufacturing](https://www.agcbio.com/hubfs/Videos/Video%20cover%20images%20CO%20SME%20interviews%20-%20Meghan%20Nelson-1.jpg)